Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome
Dimitri Poddighe,1,2 Elena Kovzel2 1Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan, 010000, Kazakhstan; 2Clinical Academic Department of Pediatrics, University Medical Center (UMC), Nur-Sultan, 010000, KazakhstanCorrespondence: Dimitri Poddighe Email dimitri.poddighe@nu...
Saved in:
Main Authors: | Poddighe D (Author), Kovzel E (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: COVID-19 and hyper inflammation syndrome: Different presentation and management
by: Dimitri Poddighe, et al.
Published: (2022) -
Impact of hypoglycemic drugs on the course of COVID-19 in patients with type 2 diabetes mellitus
by: Yasmin Ahmed Ali El-Taravi, et al.
Published: (2023) -
Design, synthesis, in vitro and in vivo biological evaluation of pterostilbene derivatives for anti-inflammation therapy
by: Liuzeng Chen, et al.
Published: (2024) -
Anti-inflammatory cytokines content in different clinical uveitis course complicated by the optic nerve inflammation
by: N.V. Panchenko, et al.
Published: (2016) -
Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19
by: Li C, et al.
Published: (2021)